A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Chemistry

• Publication date

  2007-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1373/CLINCHEM.2006.080721PMID 17463175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A CK2-dependent mechanism for degradation of the PML tumor suppressor.

  2006cited by this paper
• The human plasma proteome

  2006cited by this paper
• Mechanisms of Cancer-Induced Thrombosis in Cancer

  2006cited by this paper
• Diagnosis and Management of Epithelial Ovarian Cancer

  2006cited by this paper
• Peptidomics for cancer diagnosis: present and future.

  2006cited by this paper
• The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.

  2006cited by this paper
• Proteomics: a new diagnostic frontier.

  2006cited by this paper
• Proteomic patterns for cancer diagnosis--promise and challenges.

  2006cited by this paper
• Prediction error estimation: a comparison of resampling methods

  2005cited by this paper
• ROCR: visualizing classifier performance in R

  2005cited by this paper
• Differential exoprotease activities confer tumor-specific serum peptidome patterns.

  2005cited by this paper
• Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.

  2005cited by this paper
• Importance of communication between producers and consumers of publicly available experimental data.

  2005cited by this paper
• High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures.

  2005cited by this paper
• Signaling intricacies take center stage in cancer cells.

  2005cited by this paper
• The role of CA125 in clinical practice

  2005cited by this paper
• New tumor markers: CA125 and beyond

  2005cited by this paper
• Analysis of albumin-associated peptides and proteins from ovarian cancer patients.

  2005cited by this paper
• Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets

  2005cited by this paper
• Identification of differential genes in ovarian cancer using representational difference analysis of cDNA.

  2005cited by this paper
• Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry.

  2005cited by this paper
• Altered mRNA expressions of sialyltransferases in ovarian cancers.

  2005cited by this paper
• Concentration of histamine in serum and tissues of the primary ductal breast cancers in women.

  2005cited by this paper
• Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold.

  2005cited by this paper
• Characterization of serum biomarkers for detection of early stage ovarian cancer

  2005cited by this paper
• Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery.

  2005cited by this paper
• Discovering Patterns to Extract Protein-Protein Interactions from the Literature : Part II

  2005cited by this paper
• An investigation into the human serum “interactome”

  2004cited by this paper
• The Human Plasma Proteome

  2004cited by this paper
• A model for random sampling and estimation of relative protein abundance in shotgun proteomics.

  2004cited by this paper
• Serum proteomics in cancer diagnosis and management.

  2004cited by this paper
• Biomarker Amplification by Serum Carrier Protein Binding

  2004cited by this paper
• Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer

  2004cited by this paper
• A simple affinity spin tube filter method for removing high‐abundant common proteins or enriching low‐abundant biomarkers for serum proteomic analysis

  2003cited by this paper
• Expression of keratin K2e in cutaneous and oral lesions: association with keratinocyte activation, proliferation, and keratinization.

  2003cited by this paper
• Characterization of the Low Molecular Weight Human Serum Proteome*S

  2003cited by this paper
• Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?

  2003cited by this paper
• Status of tumor markers in ovarian cancer screening.

  2003cited by this paper
• Early detection: Proteomic applications for the early detection of cancer

  2003cited by this paper
• The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two‐dimensional electrophoresis gels and identification of 325 distinct proteins

  2003cited by this paper
• Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.

  2002cited by this paper
• Toward a Human Blood Serum Proteome

  2002cited by this paper
• Clinical potential of proteomics in the diagnosis of ovarian cancer

  2002cited by this paper
• Use of proteomic patterns in serum to identify ovarian cancer.

  2002cited by this paper
• Large-scale analysis of the yeast proteome by multidimensional protein identification technology

  2001cited by this paper
• Proteomics in early detection of cancer.

  2001cited by this paper
• Flexible Discriminant Analysis by Optimal Scoring

  1994cited by this paper

• Ovarian cancer diagnostics using wavelet packet scaling descriptors

  2024cites this paper
• The Latest Developments in Using Proteomic Biomarkers from Urine and Serum for Non-Invasive Disease Diagnosis and Prognosis

  2023cites this paper
• Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications

  2023cites this paper
• Applications of Proteomics in Ovarian Cancer: Dawn of a New Era

  2022cites this paper
• The Complement System in Ovarian Cancer: An Underexplored Old Path

  2021cites this paper
• Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis

  2020cites this paper
• Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer.

  2018cites this paper
• Mass spectrometry-based proteomics techniques and their application in ovarian cancer research

  2018cites this paper
• 5D proteomic approach for the biomarker search in plasma: Acute myeloid leukaemia as a case study

  2017cites this paper
• US 2016 / 0245818 A 1 0012

  2017cites this paper
• Application of Hydrogel Nanoparticles for the Capture, Concentration, and Preservation of Low-Abundance Biomarkers.

  2017cites this paper
• MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer

  2017cites this paper
• Differences between chronic lymphocytic leukaemia and small lymphocytic lymphoma cells by proteomic profiling and SNP microarray analysis.

  2017cites this paper
• Basics of Mass Spectrometry and Its Applications in Biomarker Discovery

  2016cites this paper
• The application of proteomics in different aspects of hepatocellular carcinoma research.

  2016cites this paper
• Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer

  2016cites this paper
• Characterization of Peptides and Low Molecular Weight Proteins in Plasma from Subjects with Hepatocellular Carcinoma

  2016cites this paper
• Clinical Predictive Circulating Peptides in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy

  2015cites this paper
• Proteomics of ovarian cancer: functional insights and clinical applications

  2015cites this paper
• Identification of potential biomarkers in Multiple Sclerosis

  2015cites this paper
• Proteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol efflux

  2015cites this paper
• Liquid chromatography-mass spectrometry based serum peptidomic approach for renal clear cell carcinoma diagnosis.

  2014cites this paper
• Deciphering the ovarian cancer ascites fluid peptidome

  2014influential citation
• Magnetic mesoporous silica incorporated with TiO2 for selective and rapid capture of peptides

  2014cites this paper
• Rapid peptidomic profiling of peritoneal fluid by MALDI-TOF mass spectrometry for the identification of biomarkers of endometriosis

  2014cites this paper
• Deciphering the peptidome of urine from ovarian cancer patients and healthy controls

  2014cites this paper
• Computational Analysis of High‐Throughput MALDI‐TOF‐MS‐Based Peptide Profiling

  2013cites this paper
• The relationship between tumor size and stage in early versus advanced ovarian cancer.

  2013cites this paper
• Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors

  2013cites this paper
• Serial Changes in Expression of Proteins in Response to Neoadjuvant Chemotherapy in Breast Cancer

  2013cites this paper
• Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer

  2013cites this paper
• Proteomics Approaches towards Early Detection and Diagnosis of Cancer

  2013cites this paper
• Collection and handling of blood specimens for peptidomics.

  2013cites this paper
• Nature of Light

  2013cites this paper
• Serum Proteomics in Biomedical Research: A Systematic Review

  2013cites this paper
• Proteomics technologies for biomarker discovery in multiple sclerosis.

  2012cites this paper
• MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment

  2012cites this paper
• From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade.

  2012cites this paper
• A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid.

  2012cites this paper
• Clinical Application of Proteomics in Ovarian Cancer Prevention and Treatment

  2012cites this paper
• Highly specific revelation of rat serum glycopeptidome by boronic acid-functionalized mesoporous silica.

  2012cites this paper
• Functional protease profiling for diagnosis of malignant disease

  2012cites this paper
• A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.

  2012cites this paper
• Impact of Whole Genome Protein Analysis on Gene Discovery of Disease Models

  2012cites this paper
• Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review.

  2012influential citation
• Proteomic technologies for identification of serum biomarkers of potential autoimmune demyelinating polyneuropathies

  2011cites this paper
• New method for peptide desorption from abundant blood proteins for plasma/serum peptidome analyses by mass spectrometry.

  2011cites this paper
• [Proteomic technologies for identification of serum potential biomarkers of autoimmune demyelinating polyneuropathies].

  2011cites this paper
• Collection and handling of blood specimens for peptidomics.

  2011cites this paper
• Combination of hydrogel nanoparticles and proteomics to reveal secreted proteins associated with decidualization of human uterine stromal cells

  2011cites this paper
• Mass spectrometry-based plasma peptide profiling of acute exacerbation in HBeAg-positive chronic hepatitis B.

  2011cites this paper
• The first decade of MALDI protein profiling: a lesson in translational biomarker research.

  2011cites this paper
• Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma with magnetic bead-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

  2011cites this paper
• Potential Markers for Detection and Monitoring of Ovarian Cancer

  2011cites this paper
• Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead

  2011cites this paper
• Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer research.

  2011cites this paper
• Variability of low-molecular-weight serum subproteome in healthy humans under the conditions of normal vital activity

  2011cites this paper
• Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer.

  2011cites this paper
• Using chromatographic and mass spectrometry tools to probe albumin and its cargos : in search of understanding type II diabetes

  2011cites this paper
• Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives.

  2010cites this paper
• An optimized procedure for the capture, fractionation and proteomic analysis of proteins using hydrogel nanoparticles

  2010cites this paper
• Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.

  2010cites this paper
• Use of SELDI MS to discover and identify potential biomarkers of toxicity in InnoMed PredTox: A multi‐site, multi‐compound study

  2010cites this paper
• High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples.

  2010cites this paper
• Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma

  2010cites this paper
• Proteomics and ovarian cancer: integrating proteomics information into clinical care.

  2010cites this paper
• Biomarkers for ovarian cancer detection and therapy

  2010cites this paper
• Questões atuais relativas à dosagem e à descrição da excreção urinária de albumina

  2010cites this paper
• Tumor markers: the potential of "omics" approach.

  2010cites this paper
• Tumor markers for early detection of ovarian cancer

  2010cites this paper
• Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery.

  2010cites this paper
• DEVELOPMENT OF A MASS SPECTROMETRY DIAGNOSTIC ASSAY TO MONITOR HEPCIDIN LEVELS IN HEMOCHROMATOSIS PATIENTS

  2010cites this paper
• [Current issues in measurement and reporting of urinary albumin excretion].

  2010cites this paper
• Optimization of solid phase PLA with emphasis on antibody modification

  2010cites this paper
• Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure

  2010cites this paper
• Using the protein chip interface with quadrupole time‐of‐flight mass spectrometry to directly identify peaks in SELDI profiles – initial evaluation using low molecular weight serum peaks

  2009cites this paper
• Challenges in cancer research and multifaceted approaches for cancer biomarker quest

  2009cites this paper
• Serum Proteomic Profiles In Subjects with Heavy Alcohol Abuse.

  2009cites this paper
• Diagnostic Parameters to Differentiate Benign From Malignant Ovarian Masses With Contrast‐Enhanced Transvaginal Sonography

  2009cites this paper
• A proteomic workflow for discovery of serum carrier protein‐bound biomarker candidates of alcohol abuse using LC‐MS/MS

  2009cites this paper
• A digital microfluidic approach to proteomic sample processing.

  2009cites this paper
• Application of proteomics in ovarian cancer: which sample should be used?

  2009cites this paper
• Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective

  2009cites this paper
• Analytical considerations for mass spectrometry profiling in serum biomarker discovery.

  2009cites this paper
• Deep depletion of abundant serum proteins reveals low‐abundant proteins as potential biomarkers for human ovarian cancer

  2009cites this paper
• The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.

  2009cites this paper
• Mass spectrometry-based clinical proteomics profiling: current status and future directions

  2009cites this paper
• Proteomics strategies for target identification and biomarker discovery in cancer.

  2009cites this paper
• Enrichment of Serum Peptides and Analysis by MALDI-TOF Mass Spectrometry

  2009cites this paper
• Serum protein profiling by solid phase extraction and mass spectrometry: A future diagnostics tool?

  2009cites this paper
• Evaluation of a type 1 diabetes serum cohort by SELDI‐TOF MS protein profiling

  2009cites this paper
• Matrix-insensitive protein assays push the limits of biosensors in medicine

  2009cites this paper
• Current issues in measurement and reporting of urinary albumin excretion.

  2009cites this paper
• Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform.

  2008cites this paper
• Proteomics of cancer of hormone-dependent tissues.

  2008cites this paper
• Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.

  2008cites this paper
• Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies.

  2008cites this paper
• Mass spectrometry in clinical proteomics – from the present to the future

  2008cites this paper
• Translationale Forschung in der gynäkologischen Onkologie: Serum-Tumormarker zur Früherkennung des Ovarialkarzinoms

  2008cites this paper
• Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions

  2008cites this paper